Related Experiment Video
Updated: Nov 17, 2025
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.0K
Challenges of Integrating Biosimilars Into Clinical Practice
Kate Jeffers1, Megan May2, Wendy H Vogel3
1UCHealth Memorial Hospital, Colorado Springs, Colorado.
Journal of the Advanced Practitioner in Oncology
|February 18, 2021
Summary
Biosimilars are highly similar to existing biologics, with no clinically meaningful differences. Presentations covered their chemical and clinical aspects, development in oncology, and strategies for effective implementation in healthcare settings.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Biosimilars represent a significant advancement in biologic therapies.
- Understanding their development and clinical application is crucial for healthcare providers.
Purpose of the Study:
- To review the chemical and clinical characteristics of biosimilars.
- To discuss the development pathways for biosimilars in oncology.
- To explore strategies for the successful implementation of biosimilars.
Main Methods:
- Discussions and presentations at JADPRO Live 2019.
- Review of scientific literature on biosimilar development and application.
Main Results:
- Key aspects of biosimilar nature and development were elucidated.
- Oncology biosimilar development was specifically addressed.
- Practical implementation strategies were shared among experts.
Conclusions:
- Biosimilars offer comparable therapeutic options to originator biologics.
- Successful integration of biosimilars requires strategic planning and education.
- Oncology treatments can benefit from the expanded availability of biosimilars.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
111
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
111
01:16Bioequivalence: Overview
1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
60
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
60
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
63
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
63
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
75
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
75
01:29Issues And Trends In Healthcare Delivery System
6.0K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.0K